Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
European Journal of Clinical Pharmacology|April 14, 2007
Tadalafil population pharmacokinetics in patients with erectile dysfunctionIñaki F Trocóniz, Christiane Tillmann, Alexander Staab, et al.Pharmaceutical Research|September 14, 2004
Population dose-response model for tadalafil in the treatment of male erectile dysfunctionAlexander Staab, Christiane Tillmann, S Thomas Forgue, et al.Journal of Pharmacokinetics and Pharmacodynamics|June 14, 2006
Model-based drug development: the road to quantitative pharmacologyLiping Zhang, Vikram Sinha, S Thomas Forgue, et al.British Journal of Clinical Pharmacology|February 21, 2006
Tadalafil pharmacokinetics in healthy subjectsS Thomas Forgue, Beverley E Patterson, Alun W Bedding, et al.British Journal of Clinical Pharmacology|July 28, 2006
Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokineticsS Thomas Forgue, Diane L Phillips, Alun W Bedding, et al.Critical Care Medicine|March 11, 2003
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failureEdward Abraham, Chris Naum, Venkata Bandi, et al.Clinical Pharmacology and Therapeutics|January 8, 2005
Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivoBarbara J Ring, Beverley E Patterson, Malcolm I Mitchell, et al.Pageof 1